They are the smallest and most helpless of victims – sometimes weighing in at less than one pound. Premature babies are surviving at younger ages than ever before only to battle with a blinding illness called Retinopathy of Prematurity(ROP). ROP is now the #1 cause of blindness in infants.
Group Headed by DEF Board Member Conducts Promising Clinical Trials - On a daily basis, consumers are flooded with advertising for the latest name-brand drugs and medical treatments. So much so, that many of us know the “cures” for ailments that don’t even afflict us.
The dedicated and continuous testing of new procedures and new drugs for safety and effectiveness is essential to the advancement of treatments of eye disease.
The Discovery Eye Foundation supports an outstanding group of physician-scientists that collaborate with ophthalmic companies to determine the safety and efficacy of new drugs and lasers that also help develop new diagnostic and therapeutic approaches.
The aim of our translational research projects is to produce information and technology that can directly help in the diagnosis and treatment of blinding eye disease. The faster we can translate what we learn in the lab into viable options for the patient, the better.
